Fig. 6. Betulin synergizes Sorafenib’s effect on HCC in situ growth in the mouse liver.

a The in situ xenograft tumors were established by injected MHCC97-H cells directly into mouse livers. Tumor-bearing mice then received vehicle control, or the indicated concentrations of Sorafenib, or 2 mg/kg Betulin or the indicated concentration of Sorafenib + 2 mg/kg Betulin orally every other day 10 times. At day 21 post treatment, mice were scanned by in vivo small-animal MicroPET imaging (N = 10). The images show the in situ tumors. b The ¹⁸F-FDG intensity analysis and quantification results. c Relative inhibitory rate of tumor growth calculated from (b). d Livers from control or tumor-bearing mice from a. e Representative tumor nodules from each treatment group. f Quantification results from e